MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

70.50 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most. ↗
At least one of these stocks owned by Alphabet could be a great pick for aggressive investors. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗
Both companies are monsters in their industry and are poised to thrive. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts ↗
Via Stocktwits
News headline image
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
2 Mega-Dividend Stocks With Yields As High As 7% ↗
Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags. 
Via The Motley Fool
Topics Economy Government Intellectual Property
News headline image
Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
News headline image
Where Will Pfizer Be in 5 Years? ↗
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Down 50%, Should You Buy the Dip on Pfizer? ↗
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Reasons to Buy Pfizer Stock Now ↗
After years of underperformance, the future is looking brighter for the drugmaker. 
Via The Motley Fool
News headline image
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October ↗
You don't need to be rich to put your money to work on Wall Street. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Things You Need to Know if You Buy Pfizer Today ↗
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗
These stocks could see growth take off over the next few years. 
Via The Motley Fool
News headline image
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial ↗
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025. 
Via Benzinga
News headline image
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out ↗
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. 
Via The Motley Fool
News headline image
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
From Metsera, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income ↗
Right now, these dividend payers are top options for folks who like to set it and forget it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Down 55%, Should You Buy the Dip on Pfizer? ↗
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? ↗
The company continues to improve its pipeline. 
Via The Motley Fool
News headline image
Pfizer is Locking in New Growth Through a New Acquisition ↗
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock? ↗
The pharmaceutical giant is again plunging headfirst into weight-loss drug development. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Passive Income Stocks to Buy Now ↗
These dividend stocks offer high yields and growth catalysts that could support payouts for decades. 
Via The Motley Fool
Topics Bonds Economy Lawsuit
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, ODP, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? ↗
Pfizer's plan to enter the booming obesity market took an expensive new turn. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story